Angiotensin II Type 1 Receptor Blockade Inhibits Gastric Cancer Metastasis Through Tight Junction Restoration

This study reveals that Angiotensin II, produced by gastric cancer cells, drives metastasis by disrupting tight junctions via the AT1R/KLF4 axis, and demonstrates that pharmacological blockade of AT1R can restore junction integrity and inhibit tumor growth and metastasis.

The Gist

The Big Picture: A Broken Fence and a Broken Lock

Imagine your stomach lining is a high-security neighborhood. The houses (cells) are held together by a sturdy, continuous fence called Tight Junctions. This fence keeps the neighborhood safe, organized, and prevents intruders (cancer cells) from escaping into the rest of the body (metastasis).

In Gastric Cancer (Stomach Cancer), this fence gets torn down. The houses fall apart, and the "bad guys" (cancer cells) slip out, travel through the bloodstream, and set up new criminal bases in the liver or other organs. This is why stomach cancer is so dangerous.

This paper discovers who is tearing down the fence, how they do it, and a clever way to fix it using a drug we already have.

---

The Villain: The "Angiotensin" Gangster

The researchers found that the cancer cells themselves are producing a chemical signal called Angiotensin II (ATII). Think of ATII as a gangster boss who lives inside the cancer cell.

1. The Autocrine Loop: Usually, signals come from outside the cell. But here, the cancer cell is shouting at itself. It produces ATII, which then hits a specific "lock" on its own surface called the AT1 Receptor.
2. The Order to Destroy: When the gangster (ATII) hits the lock (AT1R), it sends a signal that says, "Break the fence!"

The Mechanism: The "Master Key" That Was Stolen

How does the signal actually break the fence?

• The Master Key (KLF4): Inside the cell, there is a "Master Key" protein called KLF4. This key normally unlocks the instructions to build the fence (Tight Junctions). It tells the cell to manufacture the bricks (proteins like Claudin and ZO-1) needed to keep the cells glued together.
• The Theft: The gangster (ATII) hitting the lock (AT1R) steals the Master Key (KLF4) and hides it in the basement (the nucleus). Without the key, the factory stops making fence bricks.
• The Result: The fence crumbles. The cancer cells lose their grip on each other, detach, and start running away to spread the disease.

The Hero: The "Locksmith" Drug

The researchers asked: What if we stop the gangster from hitting the lock?

They used drugs called Losartan and Candesartan. These are common, cheap, and safe blood pressure medications that doctors have used for decades. They work by blocking the "lock" (AT1 Receptor).

• The Experiment: When they gave these drugs to cancer cells in a dish, the gangster (ATII) couldn't hit the lock anymore.
• The Rescue: Because the lock was blocked, the Master Key (KLF4) was released from the basement. The factory restarted, and the cells began building new fence bricks.
• The Outcome: The cells glued themselves back together. They stopped moving and stopped invading.

The Proof: Mouse Models

The researchers didn't just stop at the petri dish. They grew stomach tumors in mice.

• Untreated Mice: The tumors grew huge, and the cancer spread to the liver (metastasis). The fence was gone.
• Treated Mice: When given the blood pressure drugs (Losartan/Candesartan), the tumors shrank by about 70%, and the spread to the liver was almost completely stopped. The fence was restored.

The "What If" Test: Proving the Theory

To prove that KLF4 (the Master Key) was the only thing that mattered, they did a tricky experiment:

1. They used CRISPR gene editing to delete the KLF4 gene entirely in the cancer cells.
2. Then, they gave them the blood pressure drug.
3. The Result: The drug did nothing. The cells still ran away.

Why? Because even though they blocked the gangster, the Master Key was already gone. You can't fix the fence if you don't have the key to unlock the instructions. This proved that the drug works only because it saves the KLF4 key.

The Takeaway

This paper is a "Holy Grail" discovery for two reasons:

1. New Understanding: It explains exactly how stomach cancer breaks its own fences (ATII $\rightarrow$ AT1R $\rightarrow$ Steals KLF4 $\rightarrow$ Destroys Fence).
2. Old Drug, New Use: It suggests we can use blood pressure pills (which are cheap, safe, and widely available) to treat stomach cancer metastasis. Instead of inventing a new, expensive drug, we might just need to repurpose one we already have to "glue" the cancer cells back together and stop them from spreading.

In short: The cancer cells are using their own internal alarm system to tear down their own walls. By jamming that alarm with a common blood pressure pill, we can force the walls to rebuild, trapping the cancer in place.

Technical Summary

1. Problem Statement

Gastric cancer (GC) remains a leading cause of cancer-related mortality globally, with a poor prognosis largely driven by late-stage diagnosis and metastatic dissemination. A critical early step in metastasis is the loss of cell-cell adhesion, specifically the disruption of tight junctions (TJs), which maintain epithelial integrity. While TJ dysfunction is known to correlate with poor outcomes in GC, the molecular mechanisms driving this disassembly and potential therapeutic strategies to reverse it remain incompletely understood. The study aims to identify the regulatory pathways governing TJ integrity in GC and explore the therapeutic potential of targeting these pathways to prevent metastasis.

2. Methodology

The researchers employed a multi-faceted approach integrating clinical data, in vitro cell biology, and in vivo animal models:

• Clinical & Bioinformatic Analysis:
  • Immunohistochemistry (IHC): Analyzed human GC tissues (metastatic, non-metastatic, and normal) to assess the expression of Angiotensin II (ATII), Angiotensin II Receptor Type 1 (AT1R), Krüppel-like factor 4 (KLF4), and TJ proteins (Claudins 1, 3, 4, and ZO-1).
  • Public Databases: Utilized TCGA-STAD, UALCAN, and cBioPortal transcriptomic data to correlate gene expression (AGT, AGTR1, KLF4, TJ genes) with patient survival and disease stage.
• In Vitro Experiments:
  • Cell Lines: Used human GC cell lines (MKN45, AGS, NCI-N87).
  • Pharmacological Inhibition: Treated cells with AT1R antagonists (Losartan and Candesartan) to block the ATII/AT1R axis.
  • Genetic Manipulation: Generated KLF4 Knockout (KLF4KO) cell lines using CRISPR/Cas9 to determine the necessity of KLF4 in the observed phenotypes.
  • Functional Assays: Conducted proliferation, scratch wound healing, and Transwell invasion assays.
  • Omics & Molecular Biology: Performed RNA-sequencing (RNA-seq), Gene Set Enrichment Analysis (GSEA), qRT-PCR, Western blotting, and Chromatin Immunoprecipitation (ChIP) to elucidate molecular mechanisms.
• In Vivo Models:
  • Established orthotopic gastric cancer xenografts in athymic nude mice using MKN45 and NCI-N87 cells.
  • Treated mice with oral Losartan (10 mg/kg) or Candesartan (2 mg/kg) for 28 days.
  • Evaluated tumor growth (wet weight) and liver metastasis, followed by histological and molecular analysis of tumor tissues.

3. Key Contributions

This study establishes a novel mechanistic axis linking the local Renin-Angiotensin System (RAS) to epithelial integrity in gastric cancer:

1. Discovery of an Autocrine Loop: Identified that GC cells produce ATII, which acts in an autocrine manner via AT1R to drive metastasis.
2. Mechanistic Insight: Defined the ATII/AT1R $\rightarrow$ KLF4 $\rightarrow$ Tight Junctions signaling cascade. The study demonstrates that ATII signaling suppresses the transcription factor KLF4, which is essential for the transcription of TJ genes.
3. Therapeutic Validation: Proved that pharmacological blockade of AT1R using clinically approved drugs (Losartan/Candesartan) restores TJ integrity and inhibits metastasis in vivo.
4. Dependency Confirmation: Demonstrated that the anti-metastatic effect of AT1R blockade is strictly dependent on the presence of KLF4; in KLF4-deficient cells, AT1R inhibition fails to restore junctions or inhibit migration.

4. Key Results

• Upregulation of stRAS in GC: ATII and AT1R are significantly overexpressed in human GC tissues compared to normal stomach tissue. High expression correlates with reduced overall survival (OS) and disease-free survival (DFS).
• ATII/AT1R Drives Metastasis: Inhibition of AT1R with Losartan or Candesartan significantly reduced GC cell proliferation, migration, and invasion in vitro.
• Restoration of Tight Junctions: AT1R blockade led to a significant upregulation of TJ genes (CLDN1, CLDN3, CLDN4, TJP1) and proteins at both mRNA and protein levels. RNA-seq confirmed a positive enrichment of TJ-related gene sets upon AT1R inhibition.
• KLF4 as the Central Mediator:
  • KLF4 expression is significantly downregulated in GC tissues and correlates negatively with ATII/AT1R levels.
  • KLF4 loss (via CRISPR) resulted in the downregulation of TJ proteins and increased metastatic behavior.
  • ChIP assays confirmed that KLF4 directly binds to the promoters of CLDN1, CLDN3, CLDN4, and TJP1, acting as a transcriptional activator.
  • Rescue Experiment: ATII/AT1R signaling was shown to suppress KLF4 expression. Conversely, blocking AT1R increased KLF4 expression and nuclear localization.
  • Critical Dependency: In KLF4-knockout cells, AT1R blockade failed to restore TJ proteins or inhibit cell migration/invasion, proving KLF4 is the essential downstream effector.
• In Vivo Efficacy:
  • Orthotopic xenografts treated with AT1R antagonists showed a ~68-72% reduction in tumor weight and a significant decrease in liver metastasis compared to controls.
  • Treated tumors exhibited restored expression of KLF4 and TJ proteins, mirroring the in vitro findings.

5. Significance

• Novel Therapeutic Target: The study identifies the ATII/AT1R-KLF4 axis as a critical regulator of epithelial integrity in gastric cancer.
• Repurposing Existing Drugs: It highlights the potential of repurposing widely used, affordable AT1R antagonists (Losartan, Candesartan) as anti-metastatic agents for gastric cancer, offering a strategy to restore tissue architecture rather than just killing cells.
• Mechanistic Clarity: By elucidating the specific transcriptional repression of KLF4 by ATII, the study provides a clear molecular roadmap for how the tumor microenvironment facilitates metastasis via TJ disassembly.
• Clinical Implication: The findings suggest that patients with high ATII/AT1R expression and low KLF4/TJ integrity may benefit from AT1R blockade to prevent metastatic dissemination, potentially improving survival rates in advanced gastric cancer.